Mesa Labs CFO sells shares to cover RSU taxes

Mesa Laboratories CFO John Sakys reported an insider transaction involving company common stock.

Rhea-AI Filing Summary

Mesa Laboratories CFO John Sakys reported an insider transaction involving company common stock. On June 16, 2026, he sold 1,223 shares in an open-market sale at $101.267 per share to cover taxes arising from the vesting of restricted stock units on June 15, 2026. After this sale, he directly holds 16,538 Mesa Laboratories shares. In addition, 50 shares are held indirectly for his children, where he acts as custodian.

Insider Trade Summary 10b5-1

Net Seller: 1,223 shares

Net Sell 2 txns

Insider Sakys John

Role CFO

Sold 1,223 shs ($124K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,223	$101.267	$124K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 16,538 shares (Direct); Common Stock — 50 shares (Indirect, Custodian)

Footnotes (2)

1. F1. Shares sold to cover taxes related to the vesting of RSUs on June 15, 2026
2. F2. Consists of 50 shares held by children of which Mr. Sakys is custodian

Key Figures

Shares sold: 1,223 shares Sale price: $101.267 per share Direct holdings after sale: 16,538 shares +1 more

4 metrics

Shares sold 1,223 shares Open-market sale on June 16, 2026

Sale price $101.267 per share Price for Mesa Laboratories common stock sold

Direct holdings after sale 16,538 shares CFO direct ownership following transaction

Indirect custodian holdings 50 shares Shares held for children with CFO as custodian

Key Terms

restricted stock units, open-market sale, Form 4, Custodian

4 terms

restricted stock units financial

"taxes related to the vesting of RSUs on June 15, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The sale was disclosed in a Form 4 insider filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Custodian financial

"Consists of 50 shares held by children of which Mr. Sakys is custodian"

A custodian is a financial institution that holds and safeguards an investor's assets—such as stocks, bonds, or cash—and records transactions on the investor's behalf. Think of it as a trusted caretaker or safe-deposit box for investments; it helps prevent loss or theft, handles paperwork and transfers, and provides transparency and regulatory checks, so investors can focus on decisions rather than the mechanics or security of asset storage.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Mesa Laboratories (MLAB) CFO John Sakys report?

Mesa Laboratories CFO John Sakys reported selling 1,223 shares of common stock. The sale was disclosed in a Form 4 insider filing and is linked to covering tax obligations from recently vested restricted stock units.

At what price did MLAB CFO John Sakys sell his Mesa Laboratories shares?

He sold 1,223 Mesa Laboratories common shares at $101.267 per share. This price reflects the open-market sale reported in the Form 4 filing dated June 16, 2026, associated with RSU tax withholding.

Why did Mesa Laboratories CFO John Sakys sell 1,223 MLAB shares?

The 1,223 shares were sold to cover taxes related to the vesting of restricted stock units on June 15, 2026. Such tax-related sales are typically compensation-driven rather than discretionary investment decisions.

How many Mesa Laboratories (MLAB) shares does CFO John Sakys hold after the transaction?

After the transaction, he directly holds 16,538 Mesa Laboratories common shares. Additionally, 50 shares are held indirectly for his children, where he serves as custodian, as noted in the Form 4 footnotes.

Is the MLAB insider sale by CFO John Sakys an open-market transaction?

Yes, the Form 4 describes the 1,223-share disposition as an open-market sale. However, the footnotes clarify it was executed specifically to cover tax liabilities from RSU vesting rather than as a standalone investment decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 12:09 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sakys John

(Last) (First) (Middle)

MESA LABORATORIES, INC.

12100 W. 6TH AVENUE

(Street)

LAKEWOOD COLORADO 80228

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MESA LABORATORIES INC /CO/ [ MLAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2026		S		1,223(1)	D	$101.267	16,538	D
Common Stock								50	I	Custodian(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to cover taxes related to the vesting of RSUs on June 15, 2026

2. Consists of 50 shares held by children of which Mr. Sakys is custodian

	John Sakys	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)